• BV6: IAP Antagonism in Cell-Death Research

  2026-10-07

  BV6 is a Smac-mimetic IAP antagonist used as a research tool for studying apoptosis, treatment sensitization, and disease-model biology. This overview separates vendor-reported findings from peer-reviewed evidence and explains why apoptosis, necroptosis, and therapeutic response should not be treated as interchangeable outcomes.

• Septin4, HIF-1α, and Cardiomyocyte Apoptosis

  2026-10-07

  The 2021 study by Wu and colleagues identifies Septin4 as a previously unrecognized regulator of hypoxia-induced cardiomyocyte apoptosis. Its data support a model in which Septin4 associates with HIF-1α and strengthens VHL-dependent degradation, connecting a proapoptotic protein with impaired hypoxic adaptation while defining important boundaries for translation to HIF-targeted therapies.

• Measuring Drug Response Beyond Cell Viability

  2026-10-06

  Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, separating growth inhibition from the extent of cell killing in cancer research. This framework improves interpretation of in vitro drug-response data and clarifies why a survivin inhibitor should not be judged by a single viability endpoint.

• HyperScript™ Reverse Transcriptase for RNA Evidence

  2026-10-06

  HyperScript™ Reverse Transcriptase can support rigorous RNA to cDNA conversion when transcript abundance, RNA structure, and assay interpretation intersect. This article examines its role as a measurement component in signaling research, using IP3 receptor knockout transcriptomics to distinguish technical robustness from biological evidence.

• Acacetin–MAPK1/HMOX1 Axis in Disc Degeneration

  2026-10-05

  A 2025 Phytomedicine study reports that Duhuo Jisheng decoction and its circulating component acacetin alleviate intervertebral disc degeneration in cellular and rat models by connecting MAPK1/HMOX1 signaling, mitophagy, and nucleus pulposus cell pyroptosis. The work offers a mechanistic framework for preclinical research, while its clinical relevance remains limited by the absence of human efficacy and safety data.

• CCK-8 and Anxiety-Like Behavior in Zebrafish

  2026-10-05

  A 2020 Peptides study connected brain-wide CCK-like immunoreactivity with the behavioral effects of two sulfated zebrafish CCK octapeptides. Its comparative design showed that both molecular forms produced receptor-sensitive anxiety-like behavior, while also defining important limits on how zebrafish tank preference should be interpreted.

• Preserving Phosphosignals in Host–Pathogen Biology

  2026-10-04

  The Salmonella–FAM134B study reveals how ER-phagy shapes intracellular infection. This analysis explains why phosphorylation-aware sample preservation matters for translational interpretation and where Phosphatase Inhibitor Cocktail 3 can support rigorous phosphoprotein analysis without substituting for mechanistic controls.

• Partial BACE Inhibition and Synaptic Transmission

  2026-10-03

  Satir et al. examined whether partial β-secretase inhibition could reduce amyloid-beta production without impairing synaptic transmission. In cultured rat cortical neurons, reductions below 50% were not associated with detectable synaptic dysfunction, whereas stronger inhibition reduced both amyloid-beta secretion and transmission, defining an important model-specific boundary for Alzheimer’s disease treatment research.

• Measuring Drug Responses Beyond Cell Viability

  2026-10-01

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures in cancer drug testing. By separating growth inhibition from cell killing and considering their timing, the work provides a more informative framework for interpreting in vitro drug responses and designing survivin-focused assays.

• 8-Chloroadenosine for RNA Decay Workflows

  2026-10-01

  8-Chloroadenosine provides a time-resolved way to suppress RNA synthesis and separate transcriptional input from RNA decay in cell-based assays. This guide translates the reagent into practical workflows for lncRNA, IL-6, and cancer research, with dose-planning, controls, and troubleshooting strategies.

• Measuring Cancer Drug Responses Beyond Viability

  2026-09-30

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify how cancer drugs affect proliferation and cell death. Its central contribution is a more interpretable in vitro response framework that can improve endpoint selection, time-course design, and interpretation of epigenetic cancer studies.

• TME-Modulating Microspheres Improve TIL Therapy

  2026-09-30

  Li et al. developed alginate-based microspheres co-loaded with hyaluronidase and CXCL9 to remodel the tumor microenvironment before tumor-infiltrating lymphocyte collection. In mouse models, this pretreatment increased intratumoral TIL abundance, accelerated ex vivo expansion, improved functional properties, and strengthened control of tumor growth and metastasis after reinfusion.

• Ganetespib Assays: Reading Protein Release Correctly

  2026-09-29

  Ganetespib (STA-9090) research is usually interpreted through Hsp90 client-protein loss and viability, but extracellular signals require a more careful framework. This article applies lessons from norovirus NINJ1 biology to improve compartment-aware cancer research assays without conflating viral secretion with Hsp90 pharmacology.

• Lysoptosis: Serpin Control of Lysosomal Cell Death

  2026-09-29

  The reference study establishes lysoptosis as a conserved lysosome-dependent cell death pathway that becomes prominent when intracellular serpin protection is lost. By connecting genetic models in Caenorhabditis elegans, mouse cells, and human epithelial cells with lysosomal membrane and cathepsin-dependent readouts, it separates lysoptosis from lysosomal damage that merely accompanies other death programs.

• SkQ1 Separates Mitochondrial Apoptosis from Atrophy

  2026-09-28

  This preprint uses a metastatic ovarian cancer mouse model to test whether mitochondrial reactive oxygen species, apoptosis, or necroptosis drive skeletal muscle atrophy. Chronic SkQ1 treatment reduced mitochondrial hydrogen peroxide emission and caspase activity in late-stage disease but did not preserve gastrocnemius mass, separating mitochondrial apoptotic signaling from type II B fibre loss.

536 records 1/36 page Next 12345 下5页 Last page